Chien v. Skystar Bio Pharmaceutical Co.

623 F. Supp. 2d 255, 2009 U.S. Dist. LEXIS 49355, 2009 WL 1606451
District Court, D. Connecticut·Decided June 8, 2009·No. 3:09CV149 (MRK)·Published·Cited by 29 cases

Opinion

RULING AND ORDER

MARK R. KRAVITZ, District Judge.

Pending before the Court is Defendants’ Motion to Dismiss For Failure to State a Claim [doc. # 12], their Motion to Dismiss For Lack of Personal Jurisdiction [doc. # 13], and their Request for Judicial Notice [doc. # 14]. After the Court provided Mr. Chien notice of the Motions to Dismiss [doc. # 16], he filed a Motion for Leave to *259 Amend [doc. #22] and attached a First Amended Complaint. Defendants filed an Objection to the Motion to Amend [doc. #25], and Mr. Chien responded both to Defendants’ objection and to Defendants’ Motions to Dismiss. See Mem. in Opp’n to Mot. to Dismiss [doc. # 27]. The Court granted Mr. Chien’s Motion for Leave to Amend and dismissed with prejudice all claims from the original Complaint that were not reasserted by Mr. Chien in his First Amended Complaint. See Order [doc. # 29], The Court also informed the parties that it would consider all briefing on the Motions to Dismiss to apply to Mr. Chien’s First Amended Complaint and that no further briefing was required.

Nevertheless, Mr. Chien filed a second Motion for Leave to Amend [doc. # 30], in which he seeks to add Richardson & Patel, the law firm representing Defendants, as a Defendant in this case. The Court denies Mr. Chien’s motion. The Court has already allowed Mr. Chien to amend his complaint once and Mr. Chien has not provided any reason why he waited until this late date to seek to add an additional party, one that he was well aware of from the outset. Moreover, while “leave to amend should be freely granted when justice so requires, courts deny such leave where the proposed amendment would be futile.” Pavao v. Town of Wallingford, No. 3:08CV221(MRK), 2008 WL 2622768, at *3 (D.Conn. June 26, 2008). As explained below, Mr. Chien’s amendments are futile for a multitude of reasons. 1 Therefore, the Court denies Mr. Chien leave to amend his complaint a second time and will in this Ruling address only the claims raised by Mr. Chien in his First Amended Complaint. 2

I.

This is not the first occasion that the Court has had to address the dispute between Mr. Chien and Defendants. Mr. Chien — then represented by counsel— originally filed suit against these same Defendants in May 2007, alleging violations of §§ 10(b) and 20(a) of the Securities Exchange Act, 15 U.S.C. §§ 78j(b), 78t(a), and SEC Rule 10b-5, 17 C.F.R. § 240.10b-5. See Chien v. Skystar Bio Pharmaceutical Co., 03:07-cv-781 (MRK). After giving Mr. Chien the opportunity to amend his complaint in that first action, the Court dismissed the case in its entirety in July 2008, holding that Mr. Chien had failed to plead fraud and loss causation. Shortly before the Court dismissed his complaint, but after briefing and oral argument on the motion to dismiss, Mr. Chien’s counsel withdrew his appearance on behalf of Mr. *260 Chien, and Mr. Chien decided to proceed pro se. Defendants then filed a motion for sanctions under the Private Securities Litigation Reform Act (PSLRA), 15 U.S.C. § 78u-4(c)(l), which provides for mandatory sanctions under Rule 11 for frivolous securities actions. The Court awarded partial sanctions against Mr. Chien and his former counsel in February 2009. See Chien v. Skystar Bio Pharmaceutical Co., 03:07-cv-781 (MRK), Ruling and Order [doc. # 106]. Mr. Chien appealed both the Court’s decision dismissing the complaint and the Court’s sanctions order. See Notices of Removal [docs. # 77,118].

Meanwhile, in January 2009, Mr. Chien — still proceeding pro se — re-filed his case against Defendants in state court. Defendants promptly removed the state-court action to federal court. See Notice of Removal [doc. # 1]. Defendants then filed their Motions to Dismiss [docs. # 13, 14] and Request for Judicial Notice [doc. # 15]. Although Mr. Chien alleges many new causes of action in this second case, his new claims arise from the same events as those asserted in his first case. Thus, the Court will assume the parties’ familiarity with the facts and will not repeat them here. See Chien v. Skystar Bio Pharmaceutical Co., 03:07-cv-781 (MRK), Ruling and Order [doc. # 71] (recounting the underlying facts).

Defendants argue that the case should be dismissed on the grounds of res judicata, 3 Typically, the doctrine of res judicata, or claim preclusion, “bars not only those claims or legal theories that were asserted in the prior action, but also those legal claims or theories that could have been asserted, regardless whether they were in fact raised by the parties, so long as they arise from the same transaction that formed the basis of the prior action.” Patrowicz v. Transamerica HomeFirst, Inc., 359 F.Supp.2d 140, 153 (D.Conn.2005). The doctrine “prevents the subsequent litigation of any ground of recovery that was available in the prior action, whether or not it was actually litigated or determined.” Balderman v. United States Veterans Admin., 870 F.2d 57, 62 (2d Cir.1989). As the Second Circuit has explained:

In earlier times the doctrine of res judicata could be invoked only to bar relitigation of the same cause of action already litigated and determined.... The modern transaction view of the doctrine of res judicata, however, does not require that the claim subsequently asserted be based on [the] same cause of action to be barred, but permits the doctrine to be invoked to bar litigation between the same parties if the claims in the later litigation arose from the same *261 transaction that formed the basis of the prior adjudication.... Under the modern rule, ordinarily, a transaction gives rise to only one claim regardless of the number of ways that the claim may be asserted.

Ambase Corp. v. City Investing Co. Liquidating Trust, 326 F.3d 63, 73 (2d Cir.2003) (citations omitted); see also Johnson v. Comm’r of Correction, 288 Conn. 53, 66, 951 A.2d 520 (2008) (“The doctrine of res judicata provides that a former judgment serves as an absolute bar to a subsequent action involving any claims relating to such cause of action which were actually made or which might have been made.”).

Given that Mr. Chien’s claims in this case arise from exactly the same events (i.e., the reverse merger completed in November 2005) and includes exactly the same parties as his previous lawsuit, the Court concludes that his lawsuit is barred by the doctrine of res judicata. The new facts alleged by Mr.

Free access — add to your briefcase to read the full text and ask questions with AI

Chien v. Skystar Bio Pharmaceutical Co., 623 F. Supp. 2d 255, 2009 U.S. Dist. LEXIS 49355, 2009 WL 1606451 (D. Conn. 2009).

623 F. Supp. 2d 255 (Chien v. Skystar Bio Pharmaceutical Co.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In re: Clark
D. Connecticut, 2024
Shaik v. Williams
E.D. Oklahoma, 2024
Shaik v. Mordy
E.D. Oklahoma, 2024
Wynn v. Cassara
W.D. New York, 2023
Wynn v. Larimer
W.D. New York, 2023
Hubert v. Corrections
D. Connecticut, 2023
Lewis v. Assurant, Inc.
D. Connecticut, 2022
Temkin v. Rodrigues
D. Connecticut, 2019
Tanasi v. CitiMortgage, Inc.
257 F. Supp. 3d 232 (D. Connecticut, 2017)
Gordon Group Investments, LLC v. Kugler
115 A.D.3d 433 (Appellate Division of the Supreme Court of New York, 2014)
Marceline v. Town of Darien
974 F. Supp. 2d 123 (D. Connecticut, 2013)
Lorber v. Winston
962 F. Supp. 2d 419 (E.D. New York, 2013)